$阿斯利康(AZN)$ $强生(JNJ)$ $百济神州(BGNE)$
Q4&Full-Year 2022——IMBRUVICA decline due to global competitive pressures and a suppressed CLL market, but maintains its market leadership position
| 发布于: 修改于: | 雪球 | 转发：0 | 回复：0 | 喜欢：1 |
$阿斯利康(AZN)$ $强生(JNJ)$ $百济神州(BGNE)$
Q4&Full-Year 2022——IMBRUVICA decline due to global competitive pressures and a suppressed CLL market, but maintains its market leadership position